axitinib
Sponsor Pfizer INC · listed as PFE
axitinib is a drug asset sponsored by Pfizer INC, listed as PFE. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 31, 2026 (day precision, medium confidence), tied to trial NCT05059522. That trial is in Phase 3 and currently active not recruiting, studying Advanced Malignancies. It appears across 2 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Other tracked assets in the same trials — NCT05059522: lorlatinib, talazoparib, utomilumab.
Trials for axitinib in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT05059522 catalyst | Phase 3 | Active, not recruiting | 2026-12-31 | Experimental | Pfizer | Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors |
| NCT06364631 | Phase 3 | Recruiting | 2032-05-05 | Other | Gustave Roussy, Cancer Campus, Grand Paris | Metastatic Kidney Cancer; Metastatic Kidney Carcinoma |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More PFE catalysts